Cell surface CCR5 density determines the postentry efficiency of R5 HIV-1 infection

被引:96
|
作者
Lin, YL
Mettling, C
Portales, P
Reynes, J
Clot, J
Corbeau, P [1 ]
机构
[1] INSERM, UPR 1142, Inst Genet Humaine, F-34295 Montpellier 5, France
[2] Hop St Eloi, Immunol Lab, F-34295 Montpellier, France
[3] Hop Gui De Chauliac, Serv Malad Infect & Trop, F-34295 Montpellier 5, France
关键词
coreceptor; chemokine; activation; retrovirus life cycle; AIDS;
D O I
10.1073/pnas.242134499
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
We have recently reported that the mean number of CCR5 coreceptors at the surface of CD4(+) T cells (CCR5 density) correlates with viral load and disease progression in HIV-1-infected persons. Here, we definitively establish that CCR5 density determines the level of virus production and identify the stages of HIV-1 replicative cycle modulated by this effect. We show, by transducing the CCR5 gene into CCR5(+) cells, that CCR5 overexpression resulted in an HIV-1 overinfectability. We sorted HOS-CD4(+)-CCR5(+) cells into two subpopulations, HODhigh and HOSlow, the former expressing seven times more cell surface CCR5 molecules than the latter. Virus production was 30-80 times higher in HOShigh cells than in HOSlow cells after a single round of infection. In contrast, only twice as many viral particles entered the cytosol of HOShigh cells as compared with the cytosol of HOSlow cells. Yet, seven times as many early, and 24 times as many late, reverse transcription products were found in HOShigh cells as compared with HOSlow cells. Moreover, a 24- to 30-fold difference in the number of copies of integrated HIV-1 DNA was observed. No difference in HIV-1 LTR activation between the two cell lines was evident. Finally, we show that the higher virus production observed in HOShigh cells is inhibited by pertussis toxin, a Galphai protein inhibitor. Thus, CCR5 density mainly modulates postentry steps of the virus life cycle, particularly the reverse transcription. These data explain why CCR5 density influences HIV-1 disease progression and underline the therapeutic interest of lowering CCR5 expression.
引用
收藏
页码:15590 / 15595
页数:6
相关论文
共 50 条
  • [1] The efficiency of R5 HIV-1 infection is determined by CD4 T-cell surface CCR5 density through Gαi-protein signalling
    Lin, Yea-Lih
    Mettling, Clement
    Portales, Pierre
    Reant, Brigitte
    Robert-Hebmann, Veronique
    Reynes, Jacques
    Clot, Jacques
    Corbeau, Pierre
    AIDS, 2006, 20 (10) : 1369 - 1377
  • [2] CCR5 promoter polymorphism determines macrophage CCR5 density and magnitude of HIV-1 propagation in vitro
    Salkowitz, JR
    Bruse, SE
    Meyerson, H
    Valdez, H
    Mosier, DE
    Harding, CV
    Zimmerman, PA
    Lederman, MM
    CLINICAL IMMUNOLOGY, 2003, 108 (03) : 234 - 240
  • [3] CCR5 cell surface density and HIV-1 envelope sequences govern antiretroviral potency of CCR5 antagonists
    Miller, MD
    Lineberger, JE
    Dornadula, G
    Danzeisen, RC
    Blau, CR
    Danovich, RM
    Miller, MA
    Finke, PE
    Oates, BD
    Caldwell, CG
    Chen, P
    Meurer, LC
    Mills, SG
    Springer, MS
    Petropoulos, CJ
    Whitcomb, J
    Huang, W
    Fransen, S
    Simon, AJ
    Hazuda, DJ
    ANTIVIRAL THERAPY, 2003, 8 (03) : U66 - U67
  • [4] HIV-1 infection and CCR5Δ32 homozygosis
    Ballana, Ester
    Este, Jose A.
    FUTURE VIROLOGY, 2012, 7 (07) : 653 - 658
  • [5] Modulation of CCR5 density with low doses of the transplant drug Rapamycin sensitizes Vicriviroc-resistant R5 HIV-1
    Heredia, Alonso
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2009, 51 : 124 - 124
  • [6] Cell surface expression of CCR5 and other host factors influence the inhibition of HIV-1 infection of human lymphocytes by CCR5 ligands
    Ketas, Thomas J.
    Kuhmann, Shawn E.
    Palmer, Ashley
    Zurita, Juan
    He, Weijing
    Ahuja, Sunil K.
    Klasse, Per Johan
    Moore, John P.
    VIROLOGY, 2007, 364 (02) : 281 - 290
  • [7] CCR5 density levels on primary CD4 T cells impact the replication and Enfuvirtide susceptibility of R5 HIV-1
    Heredia, Alonso
    Gilliam, Bruce
    DeVico, Anthony
    Le, Nhut
    Bamba, Douty
    Flinko, Robin
    Lewis, George
    Gallo, Robert C.
    Redfield, Robert R.
    AIDS, 2007, 21 (10) : 1317 - 1322
  • [8] Novel low molecular weight spirodiketopiperazine derivatives potently inhibit R5 HIV-1 infection through their antagonistic effects on CCR5
    Maeda, K
    Yoshimura, K
    Shibayama, S
    Habashita, H
    Tada, H
    Sagawa, K
    Miyakawa, T
    Aoki, M
    Fukushima, D
    Mitsuya, H
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (37) : 35194 - 35200
  • [9] Targeting CCR5 trafficking to inhibit HIV-1 infection
    Boncompain, Gaelle
    Herit, Floriane
    Tessier, Sarah
    Lescure, Aurianne
    Del Nery, Elaine
    Gestraud, Pierre
    Staropoli, Isabelle
    Fukata, Yuko
    Fukata, Masaki
    Brelot, Anne
    Niedergang, Florence
    Perez, Franck
    SCIENCE ADVANCES, 2019, 5 (10):
  • [10] Maraviroc - a CCR5 antagonist for the treatment of HIV-1 infection
    Van Der Ryst, Elna
    FRONTIERS IN IMMUNOLOGY, 2015, 6